Camp4 Therapeutics Corporation (CAMP)
NASDAQ: CAMP · Real-Time Price · USD
4.505
-0.055 (-1.21%)
Apr 23, 2026, 12:30 PM EDT - Market open
Camp4 Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts that cover Camp4 Therapeutics stock have a consensus rating of "Buy" and an average price target of $8.60, which forecasts a 90.90% increase in the stock price over the next year. The lowest target is $7.00 and the highest is $12.
Price Target: $8.60 (+90.90%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Camp4 Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Buy | 6 | 6 | 6 | 6 | 6 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +55.38% | Apr 14, 2026 |
| Leerink Partners | Leerink Partners | Buy Maintains $8 → $9 | Buy | Maintains | $8 → $9 | +99.78% | Apr 2, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $7 | Buy | Initiates | $7 | +55.38% | Oct 2, 2025 |
| JP Morgan | JP Morgan | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Sep 16, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $18 → $12 | Buy | Maintains | $18 → $12 | +166.37% | Sep 15, 2025 |
Financial Forecast
Revenue This Year
2.64M
from 3.50M
Decreased by -24.47%
Revenue Next Year
3.78M
from 2.64M
Increased by 43.00%
EPS This Year
-0.80
from -2.65
EPS Next Year
-0.82
from -0.80
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 9.2M | 8.4M | ||||||
| Avg | 2.6M | 3.8M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 162.7% | 218.7% | ||||||
| Avg | -24.5% | 43.0% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.67 | -0.68 | ||||||
| Avg | -0.80 | -0.82 | ||||||
| Low | -0.91 | -0.99 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.